BioNTech (BNTX) News Today $99.23 -1.41 (-1.41%) As of 10:32 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 Time Period BioNTech SE’s BNT327 Shows Promising Results in SCLC, Earning a Buy Rating from AnalystMarch 24 at 8:48 PM | tipranks.comAnalysts Offer Insights on Healthcare Companies: Adaptimmune Therapeutics (ADAP), BioNTech SE (BNTX) and Alnylam Pharma (ALNY)March 21, 2025 | markets.businessinsider.comBioNTech SE (BNTX) Gets a Buy from Goldman SachsMarch 21, 2025 | markets.businessinsider.comLingohr Asset Management GmbH Acquires New Shares in BioNTech SE (NASDAQ:BNTX)Lingohr Asset Management GmbH bought a new position in shares of BioNTech SE (NASDAQ:BNTX - Free Report) in the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor bought 3,170 shares of the company's stock, valued at approximately $357,000.March 21, 2025 | marketbeat.comRefractory Metastatic Melanoma Pipeline Report 2025, with Focus on BioNTech SE, Y-mAbs and Therapeutics SeagenMarch 20, 2025 | globenewswire.comCharles Schwab Investment Management Inc. Purchases 53,319 Shares of BioNTech SE (NASDAQ:BNTX)Charles Schwab Investment Management Inc. increased its position in BioNTech SE (NASDAQ:BNTX - Free Report) by 39.8% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 187,355 shares of theMarch 20, 2025 | marketbeat.comBioNTech SE (NASDAQ:BNTX) Shares Sold by Primecap Management Co. CAPrimecap Management Co. CA lowered its stake in shares of BioNTech SE (NASDAQ:BNTX - Free Report) by 4.9% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 4,295,817 shares of the company'March 18, 2025 | marketbeat.comBioNTech's Pivot Into Oncology Still Makes It A Compelling InvestmentMarch 17, 2025 | seekingalpha.comBioNTech SE: Navigating Short-Term Volatility with Promising Oncology AdvancementsMarch 17, 2025 | tipranks.comBioNTech (BNTX) to Release Quarterly Earnings on WednesdayMarch 17, 2025 | americanbankingnews.comBioNTech SE (NASDAQ:BNTX) Analysts Just Slashed This Year's EstimatesMarch 16, 2025 | finance.yahoo.comVestcor Inc Has $1.13 Million Stake in BioNTech SE (NASDAQ:BNTX)Vestcor Inc increased its stake in BioNTech SE (NASDAQ:BNTX - Free Report) by 50.0% in the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 9,900 shares of the company's stock after purchasing an additional 3,300 shares during the quarter. Vestcor Inc's hMarch 16, 2025 | marketbeat.comLbp Am Sa Buys 5,085 Shares of BioNTech SE (NASDAQ:BNTX)Lbp Am Sa boosted its stake in shares of BioNTech SE (NASDAQ:BNTX - Free Report) by 2.1% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 252,918 shares of the company's stock after purchasing an addMarch 15, 2025 | marketbeat.comBioNTech (NASDAQ:BNTX) Now Covered by Analysts at CitigroupCitigroup started coverage on BioNTech in a report on Thursday. They set a "buy" rating and a $145.00 price target for the company.March 14, 2025 | marketbeat.comCitigroup Initiates Coverage of BioNTech SE - Depositary Receipt () (BNTX) with Buy RecommendationMarch 14, 2025 | msn.comBioNTech SE (NASDAQ:BNTX) Analysts Are Cutting Their Estimates: Here's What You Need To KnowMarch 13, 2025 | finance.yahoo.comBioNTech initiated with a Buy at CitiMarch 13, 2025 | markets.businessinsider.comAmundi Sells 85,658 Shares of BioNTech SE (NASDAQ:BNTX)Amundi decreased its position in BioNTech SE (NASDAQ:BNTX - Free Report) by 23.4% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 281,013 shares of the company's stock after selling 85,658 sMarch 13, 2025 | marketbeat.comBioNTech (NASDAQ:BNTX) Trading Down 6.4% Following Analyst DowngradeBioNTech (NASDAQ:BNTX) Shares Down 6.4% on Analyst DowngradeMarch 12, 2025 | marketbeat.comMorgan Stanley Cuts BioNTech (NASDAQ:BNTX) Price Target to $139.00Morgan Stanley decreased their price target on shares of BioNTech from $145.00 to $139.00 and set an "overweight" rating on the stock in a report on Tuesday.March 12, 2025 | marketbeat.comBioNTech (NASDAQ:BNTX) Given "Buy" Rating at Canaccord Genuity GroupCanaccord Genuity Group reiterated a "buy" rating and issued a $171.44 price objective on shares of BioNTech in a research note on Tuesday.March 12, 2025 | marketbeat.comBMO Capital Markets Issues Positive Forecast for BioNTech (NASDAQ:BNTX) Stock PriceBMO Capital Markets increased their price objective on shares of BioNTech from $130.00 to $143.00 and gave the stock an "outperform" rating in a research note on Tuesday.March 12, 2025 | marketbeat.comHC Wainwright Predicts BioNTech FY2024 EarningsBioNTech SE (NASDAQ:BNTX - Free Report) - HC Wainwright issued their FY2024 earnings estimates for BioNTech in a research note issued to investors on Monday, March 10th. HC Wainwright analyst R. Burns anticipates that the company will post earnings of ($5.24) per share for the year. HC WainwrightMarch 12, 2025 | marketbeat.comBioNTech (BNTX) Expected to Announce Earnings on WednesdayBioNTech (NASDAQ:BNTX) will be releasing earnings before the market opens on Wednesday, March 19, Financial Modeling Prep reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=669321)March 12, 2025 | marketbeat.comBioNTech price target lowered to $151 from $172 at TruistMarch 11, 2025 | markets.businessinsider.comBioNTech SE: Navigating Near-Term Challenges with Strategic Pipeline Opportunities and Long-Term Growth PotentialMarch 11, 2025 | tipranks.comBioNTech price target raised to $143 from $130 at BMO CapitalMarch 11, 2025 | markets.businessinsider.comBioNTech SE (NASDAQ:BNTX) Q4 2024 Earnings Call TranscriptMarch 11, 2025 | msn.comBioNTech price target lowered to $143 from $147 at BofAMarch 10, 2025 | markets.businessinsider.comBioNTech Se (BNTX) Q4 2024 Earnings Call TranscriptMarch 10, 2025 | msn.comCautious Outlook for BioNTech SE Amid Revenue Shortfall and Oncology Pipeline UncertaintyMarch 10, 2025 | tipranks.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: BioNTech SE (BNTX) and Trevi Therapeutics (TRVI)March 10, 2025 | markets.businessinsider.comBioNTech (NasdaqGS:BNTX) Faces Sales Decline To €2,751 Million In 2024 And Projects Lower 2025 RevenueMarch 10, 2025 | finance.yahoo.comBioNTech Stock Drops as Sales Outlook DisappointsMarch 10, 2025 | investopedia.comBioNTech reports Q4 EPS EUR 1.08 vs. EUR 1.88 last yearMarch 10, 2025 | markets.businessinsider.comBioNTech SE 2024 Q4 - Results - Earnings Call PresentationMarch 10, 2025 | seekingalpha.comBioNTech (NASDAQ:BNTX) Releases Earnings Results, Beats Expectations By $0.70 EPSBioNTech (NASDAQ:BNTX - Get Free Report) posted its earnings results on Monday. The company reported $1.08 EPS for the quarter, beating the consensus estimate of $0.38 by $0.70. The company had revenue of $1.19 billion during the quarter, compared to analyst estimates of $1.24 billion. BioNTech had a negative return on equity of 2.35% and a negative net margin of 15.16%. The business's revenue was down 19.5% compared to the same quarter last year. During the same period in the prior year, the company earned $1.90 earnings per share.March 10, 2025 | marketbeat.comBioNTech guides for worse-than-expected 2025 revenue declineMarch 10, 2025 | reuters.comBioNTech Reports 2024 Financial Results and Strategic Oncology AdvancementsMarch 10, 2025 | tipranks.comBioNTech Announces Fourth Quarter and Full Year 2024 Financial Results and Corporate UpdateMarch 10, 2025 | globenewswire.comBank Julius Baer & Co. Ltd Zurich Invests $7.13 Million in BioNTech SE (NASDAQ:BNTX)Bank Julius Baer & Co. Ltd Zurich acquired a new position in shares of BioNTech SE (NASDAQ:BNTX - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 56,680 shares of the company's stock, valued atMarch 10, 2025 | marketbeat.comCandriam S.C.A. Sells 80,230 Shares of BioNTech SE (NASDAQ:BNTX)Candriam S.C.A. decreased its holdings in shares of BioNTech SE (NASDAQ:BNTX - Free Report) by 8.7% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 846,934 shares of the company's stock aMarch 7, 2025 | marketbeat.com2,415 Shares in BioNTech SE (NASDAQ:BNTX) Purchased by QRG Capital Management Inc.QRG Capital Management Inc. bought a new position in shares of BioNTech SE (NASDAQ:BNTX - Free Report) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 2,415 shares of the company's stock, valued at approximately $275,000.March 7, 2025 | marketbeat.comBioNTech SE (NASDAQ:BNTX) Receives Consensus Recommendation of "Moderate Buy" from BrokeragesShares of BioNTech SE (NASDAQ:BNTX - Get Free Report) have been given an average recommendation of "Moderate Buy" by the seventeen research firms that are currently covering the stock, MarketBeat reports. Three equities research analysts have rated the stock with a hold recommendation, thirteen havMarch 7, 2025 | marketbeat.comBerenberg Bank Sticks to Its Buy Rating for BioNTech SE (BNTX)March 6, 2025 | markets.businessinsider.comBioNTech (BNTX) Expected to Announce Quarterly Earnings on MondayBioNTech (NASDAQ:BNTX) will be releasing earnings before the market opens on Monday, March 10, Financial Modeling Prep reports.March 6, 2025 | marketbeat.comWhy Moderna (MRNA) Stock Is Rallying TodayMarch 5, 2025 | msn.comGerman court rules Pfizer, BioNTech violated Moderna's COVID-19 vaccine patentMarch 5, 2025 | reuters.comSBI Securities Co. Ltd. Purchases Shares of 3,429 BioNTech SE (NASDAQ:BNTX)SBI Securities Co. Ltd. purchased a new stake in BioNTech SE (NASDAQ:BNTX - Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 3,429 shares of the company's stock, valued at approximately $391,00March 5, 2025 | marketbeat.comBioNTech stock falls after FDA clinical hold on malaria vaccine trialMarch 4, 2025 | au.investing.com Remove Ads Get BioNTech News Delivered to You Automatically Sign up to receive the latest news and ratings for BNTX and its competitors with MarketBeat's FREE daily newsletter. Email Address BNTX Media Mentions By Week BNTX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. BNTX News Sentiment▼0.890.63▲Average Medical News Sentiment BNTX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. BNTX Articles This Week▼610▲BNTX Articles Average Week Remove Ads Get BioNTech News Delivered to You Automatically Sign up to receive the latest news and ratings for BNTX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies GSK News Today Takeda Pharmaceutical News Today argenx News Today Beigene News Today Teva Pharmaceutical Industries News Today Summit Therapeutics News Today Intra-Cellular Therapies News Today Moderna News Today Genmab A/S News Today Dr. Reddy's Laboratories News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:BNTX) was last updated on 3/25/2025 by MarketBeat.com Staff From Our PartnersA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredDOGE officially begins retirement transformationElon Musk's Department of Government Efficiency ("DOGE") just announced the first-ever "fully digital retireme...Altimetry | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | SponsoredUrgent Bitcoin alert for RIGHT NOWFormer billion-dollar hedge fund manager Larry Benedict has released the most incredible presentation of his 4...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioNTech SE Please log in to your account or sign up in order to add this asset to your watchlist. Share BioNTech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy BNTX Stock Free BNTX Stock Alerts